Our data demonstrated that tumor tissues from lung adenocarcinoma patients are characterized by the presence of the putative biomarkers for the response to Mcl-1 inhibition (i.e., high expression of Bak and low expression of Bcl-xL). The gene discussed is BCL2L1; the disease is lung adenocarcinoma.